Loading...

PRQR

PRQR

PROQR THERAPEUTICS NV

(PRQR)

2026 6-K

Investor Event Announcement

25 Mar '26

2025 Results Announced

12 Mar '26

Board Changes Announced

9 Feb '26

ProQR Updates

8 Jan '26

Quarterly Results

6 Nov '25

Analyst Event Summary

3 Nov '25

Regulatory Update

20 Oct '25

Q2 Financial Results

7 Aug '25

Clinical Trial Announcement

26 Jun '25

Annual Meeting Results

3 Jun '25

First Quarter Results

8 May '25

Shareholder Meeting Announc...

1 May '25

Leadership Appointments

14 Apr '25

Annual Financial Results

13 Mar '25

Filing Amendment

12 Dec '24

Investor Event Update

11 Dec '24

Funding Announcement

11 Dec '24

Management Change

10 Dec '24

Investor Event Announcement

5 Dec '24

Q3 2024 Results

7 Nov '24

Equity Offering

25 Oct '24

Quarterly Results

8 Aug '24

Annual Meeting Results

22 May '24

Financial Results Report

9 May '24

New Program Data

8 May '24

Board Nomination Notice

23 Apr '24

Axiomer IP Defense

19 Apr '24

Year End Results

13 Mar '24

Patent Upheld

15 Feb '24

New Data Release

19 Jan '24

New Collaboration

5 Jan '24

External Links:

SEC

On January 8, 2026, ProQR Therapeutics N.V. reported encouraging safety and pharmacokinetic data for its candidate AX-0810, alongside development selections and a positive outlook for 2026. This event highlights a significant advancement for the company in its therapeutic developments.

AI Assistant

PROQR THERAPEUTICS NV

2026

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.